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Abstract
Hypoxia is one of the most probable cause of treatment failure of radiotherapy for
Head and Neck Cancer, due to the proven higher resistance of cells to radiation
when oxygen supply is reduced. The detection of tumor hypoxia, together with its
specific localization and evolution in time could be fundamental factors for patients
classification between responders and non-responders to the standard radiotherapy.
Positron Emission Tomography with 18F-fluoromisonidazole (18F-FMISO), a radio-
tracer specific for hypoxia detection, is obtaining promising results in treatment
outcome prognosis and could obtain further validation for dose painting in the fu-
ture.
In this thesis, thirty patients affected by Head and Neck Squamous Cell Carcinoma
treated with concurrent chemoradiotherapy and repeatedly imaged with FMISO
PET were analyzed. In particular, the uptake values in the images were converted
in maps of oxygen tension, closely connected to cells radiosensitivity, by the use
of a sigmoidal function. As a well-oxygenated volume is required as reference, the
first aim of this study is the determination of the influence of choosing different
references in terms of localization and pO2 level. The second objective consists
in the study of a method for a parametric characterization of the re-oxygenation
process, based on a recently proposed algorithm.
The study revealed the possibility of using as reference volume the deep neck mus-
cle, with 29 mmHg as associated oxygenation level, while the re-oxygenation mech-
anism has been characterized by a system, where the shape or the parameters of
the response could potentially predict the clinical course of the disease.
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Introduction
The potential damage that radiation can inflict to human tissues was discovered
in the end of XIX century and few years later its application in medicine to de-
feat the spread of unhealthy cells in human body began. Along the decades the
mechanisms of cells injury by radiation and of DNA repair were studied, leading
to the application of the radiation doses fractionated in different sessions, as this
generally results in a better sparing of the healthy cells surrounding the tumor [1].
The tumor microenvironment is fundamental for the understanding of its biochem-
ical properties; in particular, among them the sensitivity of cells to radiation has
a strong influence on the outcome of the treatment, with dependence on the stage
of the cell life and on the level of oxygen carried by the surrounding vasculature.
The second element is fundamental in Head and Neck Cancer (HNC), where a
great part of the patients suffers of local tumor recurrence because of more ra-
dioresistant cells; indeed, it often happens that tumors in the head and neck have
small volumes surviving in conditions of hypoxia, i.e. low levels of oxygen supply,
connected normally to a lower cells death rate when exposed to radiation. The
fractionation of the treatment in multiple doses provide one way to re-oxygenate
the tumor in between fractions, thanks to the killing of the well oxygenated tu-
mor cells surrounding the hypoxic ones: in this way the pressure due to the cell
density decreases and the vessels can better oxygenate the region. But the frac-
tionation of radiotherapy, despite allowing for re-oxygenation, normally it is not
enough efficient when adopted alone; therefore other strategies, e.g. the exposition
to hyperbaric oxygen or the assumption of radiosensitizers, have been envisaged,
giving only discrete success [2].
In order to develop more efficient strategies it is fundamental to achieve better
results in the field of hypoxia detection. From old standards methods, such as
the polarographic pO2 needle, to innovative ones, like magnetic resonance imaging
coupled to reporter molecules like 19F, all of them present important cons, e.g.
acquisitions limited by tumor accessibility, or lack of MRI systems implementing
19F imaging in humans. But so far the most widely spread molecular imaging
method is Positron Emission Tomography (PET), based on the detection of the
radiation emitted by a radiotracer injected in the patient’s body and retained by
oxygen lacking cells. Nowadays, the most used radiotracer for the detection of
hypoxia is 18F-fluoromisonidazole (18F-FMISO), considered the gold standard for
this purpose, while other tracers, possibly better in terms of image contrast, are
still under investigation [3].
While there are many studies that analyzed the prognostic capacity of this tracer,
only few articles tried to explain the mechanism of uptake, resulting in recent years
in the development of a mathematical model able to explain it. Knowing the way
with which FMISO is retained in macromolecules of hypoxic cells is of crucial im-
portance for the improvement of the therapies. Indeed, the information provided
by the tracer uptake itself could reflect the combination of multiple biochemical
processes; if instead an uptake model is available, then the actual property of in-
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terest (e.g. the oxygenation) could be imaged in a map.
The delivery of the dose is in the most of the cases given by an external source of
radiation (external radiotherapy) and several techniques, such as volumetric mod-
ulated arc therapy and intensity-modulated radiotherapy, can sterilize the tumor
volumes with high spatial accuracy. The implementation of dose boosting to the
hypoxic subvolumes through the available technology, in the future could consid-
erably improve the treatment outcome for patients affected by resistant tumors,
avoiding the appearance of tumor relapses or metastases.
Even though the use of 18F-FMISO in PET imaging is not yet allowed for "dose
painting" in radiation therapy, still it became acknowledged for its predictive power
in prognoses of HNC and for proving the presence or the absence of re-oxygenation
in the hypoxic regions.
The present thesis explored the conversion function defined by Toma-Dasu et al. [4]
that maps the values of FMISO uptake into oxygen partial pressures, in a voxel-wise
approach. In particular, the model requires as inputs a Well-Oxygenated Volume
(WOV), taken as patient-specific reference, and its assigned pO2 value: therefore,
taken for granted the correctness of the model, the accuracy of the pO2 maps ob-
tained depends completely on the choice of the two mentioned parameters. Being
the current study focused on HNC, the volumes acquired by PET imaging included
only the head and neck regions; hence, the choice of the position of the oxygenated
volume was limited to these portions of the body.
The second aim of this work was the improvement of the mathematical description
of the re-oxygenation process happening after tumor irradiation. Starting from
the oxygenation maps previously calculated, the histograms describing the distri-
bution of pO2 values in the neighborhood of the hypoxic volumes were generated
for three different time points in the therapy; here the height of each bar repre-
sented the percentage of voxels within a specific range of pO2. Subsequently, an
evaluation of the best probability distribution fitting the mentioned data was done,
associating a function, with the related parameters, to each histogram. Finally, the
re-oxygenation process was mathematically characterized by the evolution in time
of such functions.
Considering the application of the FMISO uptake model to real data, the target
for the first problem is to test the similarity of the hypoxic volumes obtained with
three different WOVs: the neck muscle, with oxygen partial pressure reference of
29 mmHg, the same with a value of 60 mmHg and a sphere in the shoulder re-
gion with pO2 equal to 60 mmHg. The similarity has been evaluated not only
between the volumes obtained with the mentioned model, but also between them
and the current conventional method used nowadays for the same purpose, based
on a threshold on the uptake values in the PET volumes. Indeed the choice of dif-
ferent WOVs influences the delineation of hypoxic subvolumes in shape, extension
and localization, therefore it is necessary to compare the results possibly to the
"ground truth"; being this information not available in practice, the target volumes
were compared to the most studied method for their delineation, thresholding the
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so called Tumor-to-Muscle Ratio in the PET images.
The second problem has been addressed with a technique that resumes the novel
method presented by Lazzeroni et Al. in 2018 [5]. The functions describing the
re-oxygenation process were obtained from the pO2 distributions by solving a prob-
lem of deconvolution and exploiting the Fourier transform.
The thesis has the following structure:
• Section 1 will give a general introduction on the radiobiological aspects of
the tumor microenvironment, indicating the various processes and factors in
cells and tissues that can alter the effect of radiations in the human body; the
effect of hypoxia on the radiosensitivity of the cells will be discussed more in
detail, together with the process of re-oxygenation.
• Section 2 reviews the imaging techniques currently available for the spatial
description of hypoxia in tumors, focusing in particular on PET imaging and
all the existent radiotracers developed for their entrapment in hypoxic cells.
Being the most studied and also the one used for this thesis, 18F-FMISO and
its uptake process will receive particular attention.
• Section 3 describes the state of the art of the different techniques and ma-
chines currently adopted in the clinics for radiation therapies, along with the
specific terminology adopted in RT for the definition of the targets. Also a
review of the goals reached so far by FMISO in prognosis of the Head and
Neck Cancers and of its expected future implementation in treatment plan-
nings is presented, together with some comparison with other radiotracers
for hypoxia. The last Subsection goes through the strategies that could be
applied for the delineation of hypoxic volumes and for dose painting.
• Section 4 describes the material available for the study, with clinical details
of the patients involved, and how the whole image dataset has been acquired;
secondly, here the methods adopted for all the image analyses are presented,
starting from the registration between different scanners to the pO2 maps
generated by using different WOVs and to the extrapolation of the parameters
related to re-oxygenation.
• Section 5 presents the results obtained, with index of similarities for the vol-
umes contoured with the methods described, and the graphical representation
of the re-oxygenation functions.
• Sections 6 and 7 are left for the discussion of the results achieved and final
conclusions are drawn.
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1 Tumor microenvironment and hypoxia - general
radiobiological aspects
A tumor is generally identified as an abnormal mass of body tissue that keeps grow-
ing relatively independently from the surrounding tissues, as tumor cells compete
with healthy host cells for space and resources evading predation by the immune
system.
The process that leads to the degeneration of this uncontrolled growth is related
to variations in the normal life cycle of cells: old or damaged cells survive when
they should die, while new cells form when they are not needed. Tumors can be
distinguished in benign or malignant (cancerous) upon their aggressiveness towards
healthy tissues: while the former have a metabolism similar to that of the host cells
and thus do not grow fast, the latter invade nearby tissues and spread through te
blood and lymph systems to other parts of the body often forming metastases [6,7].
Today one of the most applied therapies used for the treatment of tumors and
cancers is the Radiation Therapy, which story began in 1895, when X-rays were
discovered by W.C. Röntgen, and was later on developed with the discovery of
radioactivity by Henry Becquerel and Marie and Pierre Curie [8]. The potential of
radiation therapy in eradicating the tumors lies in the capacity of ionizing radiation
to interact with cells, breaking the molecular bonds in DNA and thus preventing
them from performing the normal activities and interactions with the healthy tis-
sue. The effectiveness of the therapy depends on several factors: the particles and
the energy of the rays, the fractionation scheme used, the repair time of sublethal
damages, hypoxia are some of them.
Since nowadays the precision of machinery, both for imaging and for radiation
therapy, are far away from achieving a cellular resolution, it is impossible to hit
the whole mass of tumour sparing the surrounding healthy tissue; for this reason,
to avoid unwanted damages and the generation of new tumors due to radiations,
the tolerance of the latter has to be taken as reference for the therapy. There are
numerous treatment schedules varying in time, delivered dose, number of fractions
and depending on many agents, such as the localization of the tumor, its stage of
spreading, the presence of hypoxic conditions, etc. In some cases it is suitable to
deliver one single dose to the target, but often a fractionated treatment scheme
leads to a better outcome for the patient; the choices made in the planning step
must take their bases on the radiobiological aspects of the target and of the sur-
rounding tissues.
First of all, it is important to consider the ways in which radiation induces dam-
ages that may lead to cells death and how the cells themselves try to repair such
damages. The damage can be inflicted indirectly, when the ionizing radiation has
an energy high enough to permit the break of chemical bonds between atoms or
molecules and electrons, forming ions called Reactive Oxygen Species (ROS); in
particular hydroxyl radicals, derived from water, are the biggest cause of DNA and
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protein damages in RT. On the other hand radiation can break directly the DNA
double-strand; even though this is a minor cause of DNA damage, the subsequent
death of the cell is more likely to happen, especially in case of break of both the
DNA strands [9].
Nevertheless, in case of Sub-Lethal Damages (SLD) the cell is able, in some mea-
sure, to counteract the loss of the DNA integrity going to repair (or better, to
recover) the break in the strand due to the indirect or direct effect of radiation; the
mechanism is only partially known, but in vitro and in vivo studies observed that
the recovery generally occurs in few hours (up to 6 hours) after the irradiation [10].
Thus, although in this sense fractionated RT has a lower effect on tumor tissues,
normal tissues suffer less complications concerning cells survival.
Another parameter is the Linear Energy Transfer (LET), defined as the energy
transferred to the tissue by ionizing radiation per unit track length; high-LET
radiations, condensing more energy in the same space, have more probabilities of
directly hitting the DNA double-strand and so inflict lethal damages than low-LET
radiations [11].
One of the main features to consider in RT is the cells radiosensitivity, defined as
a measure of the response to irradiation with a given dose; it is often defined as
the surviving fraction after receiving a dose of 2 Gy, where the surviving fraction
is obtained in vitro as the ratio of the plating efficiency of treated cells to that of
untreated control cells, where the plating efficiency is the percentage of seeded cells
that grow into colonies. Radiosensitivity is influenced by numerous factors, among
them being the tissue oxygenation probably the most relevant [12].
The particular condition in which the oxygen partial pressure in a specific tissue
(usually the tumor) is low is called hypoxia and it is due to the presence of a
poor vasculature and oxygen supply to the volume interested. Evidences show
that hypoxic regions are less affected by radiation exposure and that the quantity
of radiation needed to overcome this resistance with respect to normoxic tissues,
the so-called Oxygen Enhancement Ratio (OER), reaches the value of about 3 in
anoxic conditions [2]. Dose fractionation helps to re-oxygenate gradually the tu-
mor, increasing its radiosensitivity [1].
Second, cells radiosensitivity is not constant, but varies along the life cycle; the
most sensitive phase is M, when DNA is condensed and mechanisms of repair are
lacking as well as life-cycle checkpoints, while the most radioresistant is the S
phase [9]. According to the mechanism of redistribution, cells that are in a resis-
tant phase during a fraction of treatment may progress in a more sensitive phase
in the following fractions.
Last radiobiological feature to consider during the planning of a treatment with
radiation is the phenomenon of repopulation: even after irradiation tumor and host
cells keep on proliferating, leading to a sort of competition between the two popu-
lations. Repopulation of tumor cells is slow at the beginning of radiotherapy, but it
speeds up after the first doses. This is called "accelerated repopulation" and begins
after about three-four weeks of treatment for head and neck tumors. Accelerated
repopulation becomes even faster if the treatment is interrupted after the tumor
doubling time; for this reason it is preferable to postpone the start of the therapy
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than interrupting it [11].
The study of the effect of ionization on cells is described in the commonly adopted
survival curves, graphs representing the surviving fraction as function of the dose
delivered. The most adopted model used to represent the survival curves nowadays
is the Linear Quadratic (LQ) model [12], which relates the cell surviving fraction to
the dose per fraction (assuming it as constant) and the number of fractions through
the sum of two contributions: the first, proportional to the dose, is connected to
lethal damages (cell deaths), and the second, proportional to the square of the dose,
is due to sub-lethal damages, repairable within hours under normal conditions,
unless an additional radiation dose is delivered.
Figure 1.1: Surviving curve displaying the main parameters of the Linear Quadratic
model.
The formula for multiple doses in oxic conditions results:
SF = [exp(−α · d− β · d2)]n (1)
where SF is the fraction of surviving cells, n is the number of fractions and d is the
dose per fraction, while α and β express the proportion of the two contributions.
In hypoxic conditions the above mentioned formula must be corrected by the OER,
accounting for the higher resistance to ionizing radiation, as in the following:
SF =
[
exp
(
− α · d
OER
− β · d
2
OER2
)]n
(2)
The ratio α/β is useful to describe the effect of fractionation and it is the dose
for which the linear and quadratic components of cell death are equal, as visible
in Fig. 1.1, and thus represents the level of curvature of the survival in the semi-
logarithmic graph; that is, α/β expresses the sensitivity of the tissue under exam
to fractionation [12]. Average values of α/β are 10 Gy for tumor response and early
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Figure 1.2: TCP (blue curve) and NTCP (red curve) as function of the delivered
dose. Reproduced from "Basic Radiotherapy Physics and Biology" by Lasley, Foster
D. et al. with permission of Springer International. Publishing in the format
Thesis/Dissertation via Copyright Clearance Center.
responding tissues (here the response of the tissue comes earlier, without time for
recovery of sub-lethal damages) and 3 Gy for late responding tissues [10].
Therefore hyperfractionation spares the tissues with low α/β (generally late react-
ing), while hypofractionation increases the effect of radiation in the same tissues.
Furthermore, in order to give an information about the effectiveness of the thera-
pies, the concepts of Tumor Control Probabiity (TCP) and Normal Tissue Compli-
cation Probability (NTCP) have been developed. In order to achieve a successful
treatment it is essential that the dose required to sterilize the tumor is lower than
the minimum dose which may cause non-repairable damages in healthy surround-
ing tissues; the aim of radiotherapy is to maximize the therapeutic window, i.e. the
distance between the two curves, because this would lead to safer and more effec-
tive therapies (Fig. 1.2) [13]. Both TCP and NTCP curves have sigmoid shapes;
thus, the flatter and the closer to each other the two curves are, the more resistant
to radiation the tumor is.
TCP increases with the dose and decreases with the number of cells in the tissue;
the formula used to calculate it is:
TCP = e−SF ·N (3)
where N is the number of clonogenic cells in the tumor, i.e. proliferating cells.
The NTCP has a more complex expression, function of the total dose, fraction dose,
fraction number, the volume of tissue exposed to the radiation and the presence of
serial or portal organs [11].
As seen, the subject is wide, the factors involved in the outcome of RT are numer-
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ous and complex, being the mechanisms of many of them only partially known. In
the next subsections the focus will be on the oxygen effect on the radiobiology of
cells and on how the problem of the increased radioresistance can be counteracted.
1.1 Hypoxia
The research in the field of tumor hypoxia has seen in the last decade a rapid
growth in number of publications, since oxygen is one of the major key factors in
determining the radiosensitivity of cells, and consequently the outcome of radiation
and chemotherapy, especially in Head and Neck Cancers (HNC) [14].
While already at the beginning of the past century the effects of inadequate blood
flow on X-ray imaging were seen, it was only after the half of the century that
the possible consequences of hypoxia in radiation therapy were described for the
first time, thanks to the advent of in vitro clonogenic assays. It was observed that
necrosis in tumor clusters was present only if their diameter was higher than 0.4
mm, but what was more interesting to find was that, even if the size of the tumor
mass increases, the thickness of the layer of viable cells remains constant at about
180 µm, corresponding roughly to the distance from a capillary at which the oxygen
tension reaches 0 mmHg [15]. Hypoxic regions of tumors could be therefore sorts
of shells of quite constant thickness and in which the oxygen tension is at a critical
level, encompassing parts that are instead dead because of the complete lack of
oxygen.
But the scenario is actually more complex: hypoxia can have origins connected
to many parameters relative to blood vessels. A first distinction has to be made
between chronic and acute (or cycling) hypoxia; their difference lies in the duration
of the effects: while chronic hypoxia lasts from a few hours to many days, acute
hypoxia resolves in less than 2 hours, usually with a quite constant periodicity [16].
More in detail, chronic hypoxia may be sub-categorized in [16]:
• Diffusion-limited hypoxia. Here the oxygen supply is limited by the distance
to the tumor cells; the main reason for this is the absence of a robust vas-
culature near the tumor, where indeed cells started to spread irregularly and
without giving the time to the surrounding capillaries to adequate their net
of blood distribution and letting thus the oxygen to diffuse to all the cells in
the tumor.
• (Chronic) hypoxemic hypoxia. Due to the constant reduction of oxygen con-
tent in the blood and/or a very high oxygen gradient along the vessels; the
causes are related to anemia, functional anemia (heavy smokers decrease the
availability of hemoglobin due to its binding with carbon monoxide) or oxygen
supply coming from a vein.
• Hypoxia due to compromised perfusion of leaky microvessels. Being the mi-
crovessels in tumor areas dilated, tortuous and usually leaky, the gradient of
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pressure between the arterial and venous ends decreases easily to 0 mmHg,
because of the transmural coupling (in tumor tissues the interstitial fluid has
higher pressure compared to the microvascular one).
When talking of acute hypoxia, it is possible to refer to [16]:
• Ischemic hypoxia. It is connected to a temporary block or a heavy reduction
of the blood perfusion in a vessel, due e.g. to fibrin clots or masses of tumor
cells obstructing its aperture, but also to vascular remodeling.
• (Acute) hypoxemic hypoxia. Transient and sharp reduction in the oxygen
content in tumor microvessels, relative to temporary plasma flow or reduction
in the number of red blood cells, besides possible common flow reversal in
the capillary bed.
The consequences for each subtype of hypoxia are different in terms of perfusion,
oxygen (and also nutrient) supply and waste removal, but they can be easily de-
duced by the above mentioned descriptions. Nowadays only few studies analyzed
the biological and clinical effects of the two macro categories of hypoxia and they
are often inconsistent; but what is generally found is the development of a more
aggressive phenotype after acute hypoxia than after chronic hypoxia [17].
To give some reference numbers, hypoxic conditions are related to similar shapes
in the survival curves, but the dose needed to reach a certain level of survival can
reach 3 times the one needed in normoxic conditions and this value keeps constant
at all levels of cell survival, making useful in this context to use a reference index
as the OER [2].
The OER as function of the oxygen partial pressure has a fast growth till a tension
of about 30 mmHg, then stabilizes at an almost constant level for all the following
values of pO2. Well-oxygenated tissues have oxygen partial pressure values of 30-
70 mmHg [18], while the threshold for hypoxic ones is usually fixed at 10 mmHg,
because this is the limit partial pressure at which some critic metabolic processes
start to fail [19].
To overcome the problem of hypoxia, both acute and chronic, in radiation therapy
five categories of aids have been explored in the last decades [20,21]:
• Increased oxygen delivery by the blood
– Hyperbaric oxygen breathing. It consists in the administration of oxygen
under several atmospheres (generally 3) to the patient, with the aim
of saturating the blood plasma and so extend the limits of the oxygen
perfusion around capillaries, including in this way the hypoxic cells.
Even though this technique gave better results in terms of tumor control
in several clinical trials, it does not assure that the oxygen reaches the
hypoxic regions; moreover it could give complications to other tissues,
like some kinds of cartilage, which by nature have a low oxygen tension.
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– Normobaric oxygen/carbogen breathing and/or nicotinamide. Carbogen
with a mixture of 95% of oxygen and 5% of carbon dioxide at am-
bient pressure can reduce the level of chronic hypoxia in the tumor,
while the joint administration of nicotinamide helps also the treatment
of perfusion-limited hypoxia.
– Blood transfusion. Transfusions of blood with high concentrations of
red blood cells in patients with hypoxic Head and Neck Squamous Cell
Carcinoma (HNSCC) and low levels of hemoglobin have been tested in
several clinical trials, however results did not demonstrate any significant
improvement in the tumor oxygenation [22,23].
• Mimic of oxygen in the radiochemical process.
– Radiosensitizers. These molecules resulted to have similar, but weaker,
effects to oxygen in the radiochemical process, reaching OERs of 1.5-
2; in particular 5-nitroimidazoles and 2-nitroimidazoles have been the
most studied radiosensitizers, while 2-nitroimidazoles utilization in the
last decades moved towards the imaging sector of hypoxia. The limit of
these compounds is their toxicity for the nervous system at the doses
required. To date there is only one radiosensitizer, the nimorazole, used
in HNC in the standard RT treatment.
• Destruction of hypoxic cells.
– Hypoxic cytotoxins. Several selective cytotoxins towards hypoxic cells
have been developed; nowadays it seems promising and worth of note
a derivative of 2-nitroimidazoles, TH-302, currently in clinical develop-
ment.
Nitroimidazoles revealed themselves to produce cytotoxic metabolites
specific towards hypoxic cells, but on a lower scale.
– Hyperthermia. Pre-clinical studies showed that the heat can sensitize
and eventually kill hypoxic cells when the tumor is contemporarily irra-
diated and taken to a temperature of 43◦C; this is most probably related
to the inhibition of DNA recovery.
• Vascular targeting agents.
– Angiogenesis inhibiting agents - vascular disrupting agents. One way to
prevent the formation of hypoxic tumors, but also tumors in general, is
to counteract their growing vasculature. Angiogenesis inhibiting agents
inhibit several steps in the angiogenic process, while vascular disrupting
agents damage already existing tumor vessels. Despite their promising
effects, it seems necessary to use them as coadjuvants in radiotherapy,
because they do not increase the tumor control when used alone.
• Radiation-based approaches.
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– high-LET radiation. The OER, besides to depend on the oxygen tension,
is a quantity function also of the kind of radiation used: radiation with
low-LET, X or γ-rays for instance, present higher OER (from 2.5 to 3)
than the ones with high-LET, such as α-particles (close to 1); therefore
the dependency on the oxygen tension is almost null for α-particles [24];
here hypoxia passes in background in the treatment planning. Never-
theless, hypoxia can be completely ignored only when the LET value
exceeds 500 keV/µm, a value not achievable clinically nowadays.
1.2 Re-oxygenation
The phenomenon of re-oxygenation appears when, after radiation exposure, most of
the oxic tumoral cells die due to their higher radiosensitivity, while the surviving
cells, mainly hypoxic, gradually achieve better vasculature and oxygenation and
their radiosensitivity increases. In fractionated radiation therapy re-oxygenation
happens through two modalities, connected to the two macrocategories of hypoxia
described in the previous section [25]:
• Slow re-oxygenation. Connected to the diffusion-limited hypoxia, slow re-
oxygenations happens when the ionizing radiations kill the more sensitive
tumor cells near the capillaries, allowing a reduction of the interstial pressure
and the revascularization of the area; as dead cells cannot consume oxygen
anymore, hypoxic cells can reach higher oxygen tensions and reduce their
radioresistance. This process is repeated fraction after fraction, helping to
move the hypoxic layer towards the inner core of the tumor mass; the desired
result is a small volume of well-oxygenated cells, more easily eradicable by
the ionizing radiations (Fig. 1.3). The processes of slow re-oxygenation can
last from some hours to several days.
• Fast re-oxygenation. In the context of acute hypoxia it is possible that the
death of some irradiated cells obstructing the lumen of tumor microvessels can
turn in their opening, restoring the blood flux within minutes to few hours; or
the same effect may be due to a possible migration of few cell diameters. An
important difference from the previous kind of re-oxygenation is the vitality of
the hypoxic cells: while in slow re-oxygenation cells are starvating because of
a chronic lack of oxygen, here cells are only temporarily deprived of it and can
go on with their metabolic activities rapidly after recovering the supply; the
consequence of this is an higher difficulty in the treatment of cyclic hypoxic
cells when compared to the other because of the different sub-lethal damage
repairing times.
However, despite its utility in achieving better treatment outcomes, the mechanism
of tumor re-oxygenation nowadays is not yet fully understood and is matter of
research.
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Figure 1.3: Fractionated radiotherapy and re-oxygenation. Reproduced from "Basic
Radiation Oncology" by Beyzadeoglu, M. et al. with permission of Springer Nature.
Publishing in the format Thesis/Dissertation via Copyright Clearance Center.
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2 PET imaging of hypoxia
One of the major problems related to hypoxia since it began to be studied is its
detection in vivo. Before the 1990s, effects of hypoxia were analyzed through ra-
diation responses comparisons between the tumors of interest and tumors made
anoxic in mice and rats; however this approach is qualitative and not suitable for
the clinical practice, so researchers developed several techniques to quantify, di-
rectly or indirectly, the levels of pO2 in tumors [2].
The polarographic pO2 electrode (based on the O2 Clark’s electrode principle) has
been considered for long time the gold standard for quantitative measure of tumor
hypoxia; however, despite providing a direct measure of pO2, it has a non-negligible
effect on the actual levels of oxygen tension, only a specific part of the tissue pO2
is represented and last, the procedure is particularly invasive and can damage the
tissues [18]. After that, indirect measures of oxygen tension have been explored;
particular signal sequences of Magnetic Resonance Imaging (MRI) paired with in-
jected fluorocarbon reporters can give quantitative measure of hypoxia in tumors,
however the limit of this procedure is the lack of human MRI systems supporting
19F MRI. Blood Oxygenation Level Dependent (BOLD) MRI instead is a qualita-
tive way to establish changes in the vasculature in tumors, although variations in
signals are also connected to changes in oxy- and deoxy-hemoglobin concentrations,
blood flow and vascular volume. Electron spin resonance, based on concepts sim-
ilar to NMR, but imaged with spectrometers, has also been explored; its coupling
with specific reporter molecules, such as char crystals or phthalocyanine, notably
revealed sensitivity to oxygen content in tissues. However, the best results are
given by direct injection of these compounds into tumor tissues, in order to avoid
measurements biased by the uptake in the background tissues [3].
But probably the ideal way in which hypoxic cells could be detected would be one
in which a molecular probe is not trapped when O2 supply satisfies the demand of
the cells and is instead retained when the oxygen supply is inadequate to permit the
normal cellular respiration; moreover, since hypoxia is related to poor vasculature,
it is important that this probe is delivered to all cells independently of the blood
flow. Several molecules have been found to fulfill these requirements; in particular
2-nitroimidazoles, which at the beginning were used as radiosensitizers for hypoxic
cells, demonstrated to give better results when labeled to image hypoxia through
Positron Emission Tomography (PET) [3].
The late advent of PET in diagnosis and prognosis of tumors is due mainly to the
delayed advances in the instrumentation technology with respect to those of syn-
thetic chemistry, but now its sensitivity and versatility make it the most powerful
molecular imaging technique for clinical use today available. Moreover its coupling
with specific hypoxia tracers shifts its initial use from the detection of cancers to
evaluation of their prognosis, with consequent selection of the most adapt treat-
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(a)
(b)
Figure 2.1: PET scanners produce functional images thanks to the radioactivity
of injected radiotracers in the patient’s vascular system. 2.1a shows a modern
PET/CT scanner (the one also used for this thesis). Reprinted with permission
from Philips. 2.1b represents a functional image obtained with the radiotracer
18F-FMISO, used for detection of tumor hypoxia.
ment for the specific patient. Fig. 2.1 shows a modern PET/CT scanner and a
typical functional image obtained through the use of 18F-FMISO, a radiotracer
adopted for the identification and delineation of tumor hypoxia.
PET machinery coupled also with Computer Tomography (CT) imaging can be
adopted for different uses in oncology [26]: differentiation between malignant and
benign tumors; primary tumor and metastases localization; grading malignancy,
based on the concentration of tracer uptake; staging of cancer through full-body
imaging; identification of residuals after the treatment; localizing eventual recur-
rences; measuring the effectiveness of the therapy adopted; guidance in radiation
therapy, for radiation boosts in more radiosensitive areas of the tumor.
2.1 Radiotracers for hypoxia imaging
PET radiopharmaceuticals are generally classified upon their ability to image a
specific biochemical process or on their process of localization in a specific organ or
tissue of interest [27]. The development of radiotracers for hypoxia has focused al-
most only on 2-nitroimidazoles, as different studies showed that they act as oxygen
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mimetics (even if their affinity is lower than the oxygen) and are trapped in cells
that are hypoxic but still have electron-transport activity, i.e. hypoxic cells still
alive, being the oxygen tension at a critical level, but not below 2-3 mmHg [28–30].
Before describing why 2-nitroimidazoles are so effective for the imaging of hypoxia
(and what are their possible limits), it is worth discussing which are the main
factors to consider before the development of a radiotracer [27]:
• Size of the molecular imaging probe. The dimension of the probe will deter-
mine how rapid is its clearance from nonspecific areas and from the blood
circulation: the faster the washout, the higher will be the tumor to back-
ground ratio. This can be accomplished by smaller molecules; however it
turns in lower specific activity, being restricted the possibility of binding
more than one radiolabel per molecule.
• Position of the radiolabel. The localization of the radiolabel in the probe
molecule must not influence its natural pharmacologic and chemical proper-
ties.
• Lipophilicity. The affinity towards lipophilic environments is highly depen-
dent on the molecular mass, size and hydrogen-bonding capacity (polarity).
This is an important parameter for the determination of the pharmaco-
kinetics and dynamics properties of the radiolabel, such as the distribution
in the tissues and its metabolism and elimination. It is generally calculated
through an experiment involving the partition of the tracer between octanol
and a buffer (commonly water).
• Nonspecific binding. The binding to proteins in blood plasma or to cell mem-
branes are often occurrent, reducing in this way the amount of radiotracer
available for the imaging of the target.
• Specific activity. It is the number of probe molecules capable of giving an
useful radioactive signal for a given mass of radiotracer. It should be the
highest possible, in order to prevent the saturation of the specific binding
sites, with consequent decrease of contrast.
2-Nitroimidazoles are most commonly labeled with PET radionuclides such as 18F
or 124I, but also 123I or even 99mTc can be used. Anyway for the development
of PET radiopharmaceuticals, 18F appears to be an ideal radionuclide; indeed,
compared to other radiolabels, it takes several advantages, such as a relatively
high specific activity, the possibility of production in high amounts, high resolution
images (with a maximum of about 2.4 mm) and a half-lime time of 110 minutes,
which is suitable for the transport from the cyclotron of production to the clinic [26].
For what concerns the probe molecules themselves, one strong advantage of 2-
nitroimidazoles has been discovered in in vitro cultured cells and this becomes
clear in Fig. 2.2: the range of oxygen partial pressures at which 2-nitroimidazoles
are retained corresponds to the range at which OER varies steeply from about 3 in
normoxic tissues to 1 in hypoxic ones, resulting in higher severity of hypoxia when
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Figure 2.2: Uptake (arbitrary units) of 3H-FMISO (left axis and solid line) and
oxygen enhancement ratio (right axis and dashed line) as function of oxygen pres-
sure. Reprinted from "Molecular Imaging of Hypoxia" by Krohn, Kenneth M. et
al. J Nucl Med. 2008; no. 49, pp. 129-148. c© SNMMI.
the tracer uptake grows [3].
The radiotracers derivating from 2-nitroimidazoles currently studied for imaging of
hypoxia are:
• 18F-FMISO, 18F-fluoromisonidazole;
• 18F-FETNIM, 18F-fluoroerythronitroimidazole;
• 18F-FETA, 18F-fluoroetanidazole;
• 18F-FAZA, 18F-fluoroazomycin-arabinofuranoside;
• 18F-HX4, 18F-flortanidazole.
Another tracer, belonging to another family of compounds, is matter of research
for hypoxia:
• Cu-ATSM, Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone)
In 1984, 18F-FMISO was proposed as a tracer for determining tumor hypoxia and
nowadays is considered the gold standard for the assessment of hypoxia in PET
imaging. So far it has been used to quantify tumor hypoxia in lung, brain, head-
and-neck cancer patients and in the hearts of patients with myocardial ischemia.
The reason why 18F-FMISO is considered to be a good radiopharmaceutical prog-
nostic for hypoxia lies in the fact that image pixels with a Tissue-to-Blood Ratio
(TBR) equal or smaller than 1 are reliably normoxic. However, because of its
dynamics in the human body (high lipophilicity, slow clearance kinetics, reaction
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mechanisms and only passive transport), the identification and quantification of hy-
poxic tumor areas necessitate imaging for longer periods of time post injection [26].
18F-FETNIM is more hydrophilic than 18F-FMISO and thus can be washed out
more rapidly from well-oxygenated tissues compared to 18F-FMISO in preclinical
studies and its synthesis is also simpler. In spite of the promising results, they need
to be confirmed on a larger scale in order to be applied in the clinical practice [31].
18F-FETA is more stable to non-hypoxic degradation in vivo, while its uptake re-
flects the pO2 in the range 1-10 mmHg [3]; however it shows a less rapid metabolism
by the body than 18F-FMISO [26] and further studies are needed to confirm its
properties.
18F-FAZA displayed a hypoxia-specific uptake mechanism and shows faster clear-
ance than 18F-FMISO, providing high tumor-to-background ratios in less time [32].
Even its research is at a pre-clinical level and has not been adopted yet for tumor
prognosis of patients.
18F-HX4 is a novel radiopharmaceiutical derivated from 2-nitroimidazoles that
showed reliable results in the definition of the hypoxic target, with faster wash-
out times, higher contrast and sensitivity when compared to 18F-FMISO, even
though only few studies have been conducted on human patients [33–35].
Cu(II)-ATSM instead plays a role in determining hypoxic regions through a mecha-
nism of oxido-reduction, its uptake is more rapid than 18F-FMISO uptake, and the
reported tumor-to-background ratio is about 3 times larger; despite this, the pro-
cesses of uptake and clearance of the tracer are not yet completely understood [32].
2.2 18F-FMISO biochemistry
The molecule of 18F-fluoromisonidazole (Fig. 2.3), despite the different structure
from other 2-nitroimidazole analogs, has similar mechanism of trapping in hypoxic
cells.
Nitroimidazoles enter cells by passive diffusion and, thanks to the affinity of the
nitro group for electrons, undergo a single electron reduction (with the electron
coming from the respiratory cycle of the cell) to form -NO2, a potentially reactive
radical anion, through the action of the enzyme nitroreductasi. When the oxygen
concentration is high in the tissue, a molecule of O2 accepts the electron from
the anion, reoxidizing it. Instead, under hypoxic conditions, further reduction of
the nitroimidazole occurs forming covalent bonds to intracellular macromolecules,
leading to the entrapment of the probe in the hypoxic cell (Fig. 2.4) [3, 26]. Then
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Figure 2.3: 18F-FMISO molecule. Adapted from "18F-Labeled Positron Emission
Tomographic Radiopharmaceuticals in Oncology: An Overview of Radiochemistry
and Mechanisms of Tumor Localization", no. 37, Vallabhajosula S., pp. 400-419,
Copyright 2007, with permission from Elsevier.
the bound radiolabeled tracers can be visualized with PET imaging, giving infor-
mation about the hypoxic volume of the tumor.
Figure 2.4: The mechanism of intracellular trapping of nitroimidazoles. Reprinted
from "18F-Labeled Positron Emission Tomographic Radiopharmaceuticals in On-
cology: An Overview of Radiochemistry and Mechanisms of Tumor Localization",
no. 37, Vallabhajosula S., pp. 400-419, Copyright 2007, with permission from
Elsevier.
The imaging protocol normally adopted for 18F-FMISO is quite simple, even though
some differences in the timing issue are present among the different studies. When
patients come to the clinic they are not required to fast before the study; the nec-
essary dose of radiotracer (normally dependent on the weight of the patient) is
injected and a static image acquisition starts from 90 to 120 minutes later with
a duration of about 20 minutes, in order to collect a discrete number of emission
events and get thus an higher contrast, even though lower compared to other radio-
tracers for hypoxia. Actually several studies showed that the contrast between the
tumor and the background tends to increase (at least for 6 hours in rats, 4 hours in
humans), without reaching a plateau in clinical useful time [36,37]; for this reason
the general trend in the last years is to adopt an interval of 4 hours post injec-
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tion before the start of the static imaging. Normally during the imaging session
a venous blood sample is drawn and the 18F-FMISO blood concentration is used
to obtain a normalized map of Tumor-to-Blood Ratio (TBR) for each pixel in the
image [3]. However in some cases this information could be missing, so it becomes
necessary to use a reference region containing a well-oxygenated tissue; the choice
of the reference is not univocal, because several factors, such as the position of the
patient or partial body images, may interfere and lead to different results after the
normalization; a common reference region for HNC is the posterior neck muscle
and, instead of the TBR, a new parameter, the Tumor-to-Muscle Ratio (TMR) is
adopted.
These maps are useful for the localization of hypoxic regions through the definition
of a threshold on the TBR or TMR; Table 1 shows typical values reported in the lit-
erature concerning the TMR according to the protocol used. The values displayed
could (in theory, if 18F-FMISO or other radiotracers will be validated for hypoxia
imaging) be used for the treatment planning, considering an escalation of the dose
accordingly to the levels of uptake [4, 36]. Despite the simplicity of directly using
the uptake values, a map of pO2 values would define more accurately the biophysi-
cal conditions and thus the treatment dose could be shaped according to the levels
of oxygen tension, that generally are assumed to come from a nonlinear conversion
function [4].
A novel sigmoidal conversion function based on the fitting of in vitro experimental
data has been proposed in 2009 by Toma-Dasu et al. [4]:
pO2(r) =
C · (A− Uptake(r))
B + Uptake(r)−A (4)
where r is the voxel in analysis, A , B and C are reaction-specific parameters,
which for 18F-FMISO result to be A = 10.9, B = 10.7, C = 2.5 mmHg [38]. More
specifically the parameter A is related to the reaction speed in the absence of the
inhibitor and the second term (with parameters B and C) describes the inhibition
effect.
The Uptake parameter in equation 4 is given by the uptake value in the voxel r
in the FMISO PET, divided by the mean value in the selected Well-Oxygenated
Volume (WOV) and multiplied by the tracer uptake obtained when equation 4 is
applied using the reference pO2 value for the WOV.
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3 Head and Neck radiotherapy with external beams
Radiotherapy is a term coined in 1903 by Emil Grubbe, an American medical stu-
dent who was most probably the first to apply radiation for clinical purposes [11].
Since then the field of radiation oncology spread and developed in the medical and
scientific community. Its importance nowadays is underlined by the fact that more
than 50% of cancers require radiotherapy, while about 25% may need a second
radiation treatment due to recurrences [52, 53]. However in the clinical practice
most of the cases are treated with a combination of different modalities, such as
surgery, medical oncology, nuclear medicine and radiology.
Cancers are generally diagnosed basing on the stage of spreading (eventual metas-
tases increase the severity of the pathology) and the area in which the primary
tumor started to grow. In particular, Head and Neck Cancers are the ones in-
volved in this study; about 630.000 patients are diagnosed of HNC cancer every
year in the world, while the death incidence is over 55%, involving especially Head
and Neck Squamous Cell Carcinomas (HNSCC). Many are the reasons that can
promote the development of HNC: they can arise because of bad habits (smok-
ing and alcohol are the most correlated to HNSCC; use of dry snuff, particularly
adopted in Sweden and USA, is highly correlated to Oral Squamous Cell Carcinoma
(OSCC)); viral infections, such as papilloma virus (HPV) ia another possible cause
of HNC; genetic tendency plays a role as well; even the exposure to radiation (for
instance previous radiotherapy) and to sun may be cause of skin carcinoma; other
possible risk factors are vitamin deficiencis, poor oral hygiene, chronic infections
and prostheses characterized by low biocompatibility with human tissues [11,54].
Independently on the location of the cancer, the kinds of radiation therapy can be
distinguished upon the aim: it may be curative, especially when the cancer volume
is limited and localized in a specific site; palliative, for instance in case of metas-
tases, in order to alleviate the symptoms; preventive, when the aim is to prevent
possible metastases or recurrences; total body irradiation, for suppression of the
immune system when the bone marrow needs to be transplanted. It is opportune
to specify in this context that in the head and neck region the lymphatic network
is particularly rich of vessels and each site-specific cancer has its specific route for
lymph node metastasis [11].
3.1 Generalities on type of external beam radiotherapy
According to the location of the radiation source, radiotherapy may be classified
in [11]:
• External radiotherapy (teletherapy/external beam radiotherapy). Radiother-
apy applied to the body externally using a treatment machine.
23
• Brachytherapy (endocurietherapy/sealed-source radiotherapy). Radiotherapy
based on placement of permanent radiation sources in body cavities.
• Intraoperative radiotherapy. Kind of radiotherapy delivered usually through
low-LET beams immediately after the surgical resection of the primary tu-
mor.
As this study focuses on external beam radiotherapy, it is necessary to have a
general look on the different techniques and machines nowadays adopted for cancer
treatment with the radiation dose being delivered from outside the body. They
are [11,55–57]:
• Image-Guided RadioTherapy (IGRT). It involves coregistered anatomical (CT,
MRI and ultrasounds) and functional (fMRI, PET) imaging techniques to in-
crease the precision of the therapy, accounting for variations in volume and
shape of the target during the treatment and adapting to them. It can be
included in other techniques.
• Stereotactic Body RadioTherapy (SBRT). Radiotherapy delivered by several
beams based on a 3D model of the target volume. The requisites of this
technique are: secure patient immobilization through customized molds for
the body; accurate tumor relocalization with the assistance of IGRT tech-
niques; a system solving the problem of movements due to respiration (in
case of liver and lung tumors), e.g. X-ray tumor tracking. It is different
from Stereotactic RadioSurgery (SRS), most adopted for brain recurrences
or metastases, while SBRT is applied to lung and lymph node cancers and
lung, spine, bony metastases. The main benefit of these approaches is the re-
duction of the length of the therapy (hypofractionation) through the delivery
of higher doses, sparing in a better way the normal tissues than conventional
RT.
• Three-Dimensional Conformal RadioTherapy (3D-CRT).A technique by which
the dose volume is made to conform closely to the tumor volume through the
use of 3D anatomical data coming from CT or MRI imaging. Recent 4D-CRT
treatment plannings include in the analysis also the breathing movement, de-
signed especially for treatment of non-small cell lung cancer (NSCLC).
• Intensity-Modulated RadioTherapy (IMRT). An evoluted form of 3D-CRT,
according to which the dose distribution that conforms to the target is com-
posed by non-uniform beam intensities, permitting a more effective sparing of
normal tissues and local dose boosts to less radiosensitive volumes (especially
when IGRT is supported).
• Tomotherapy. A particular IMRT technique consisting in the delivery of the
dose in slices in a serial or helicoidal mode.
24
• Volumetric Modulated Arc Therapy (VMAT). A novel radiation technique
based on the simultaneous variation of three parameters during the dose
delivery: the gantry rotation speed, the shape and aperture of the beam and
dose rate.
• CyberKnife R©. A kind of SBRT/SRS technique in which a linear accelera-
tor mounted on a robotic arm with 6 degrees of freedom delivers the dose
volume from numerous points in space (nodes, normally 100-200) spherically
distributed around the patient. The possibility of mounting a linear acceler-
ator (linac) on a robotic arm is due to the smaller dimensions with respect to
normal linacs; indeed this machine works in the X-band (wavelength: 2.5-3.75
cm) instead of the normal adopted S-band (wavelength: 7.5-15 cm). Accurate
detection of target motion and tracking of the radiation beams are ensured by
a pair of stereoscopic in-room X-ray tubes and associated flat panel detectors;
although the imaging is in 2D, and not 3D given by Cone-Beam CT (CBCT)
as in many other units, this gives an advantage in terms of speed of detection,
processing and corrections of the robotic manipulator. Moreover the recent
addition of multi-leaves collimator to the assembly lets the modulation of the
dose giving an IMRT/SBRT combined modality.
• Gamma Knife Icon (GKI). Kind of SBRT machine capable of managing more
than 10 isocenters for the treatment of complex tumors thanks to the presence
of 192 radiation sources positioned in a CT round shape. A CBCT imaging
unit is integrated and aligned with the radiation unit for online correction of
the treatment.
Furthermore, even a number of different types of radiation beams are used for radio-
therapy. These include X-rays, electrons and other particles like neutrons, protons,
negative pi-mesons, as well as heavier nuclei such as carbon, helium, neon, and
silicon ions.
When planning the treatment essentially three types of volumes need to be defined
by the medical team [58,59]:
• Gross Tumor Volume (GTV). Macroscopic contouring of the most cell dense
malignant growth to determine its localization and extension; it is based
on anatomical and/or functional images, palpation or visual analysis (when
superficial). It includes the primary tumor and eventually lymph nodes or
other metastases.
• Clinical Target Volume (CTV). It includes the GTV and a margin accounting
for spreads of the tumor cells into nearby tissues; here the tumor cell density
is lower, nevertheless this region needs to receive a certain dose if the aim is
a curative therapy, as in this case only the eradication of all the tumor cells
leads to a successful RT treatment.
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• Planning Target Volume (PTV). It encompasses the CTV and is related to
the precision of the machinery used for the imaging and the treatment. It is
defined by the Systematic Target Volume (STV) plus a random error mar-
gin: while the former accounts for errors in treatment preparation, the latter
considers all the possible accuracy errors that may arise during the treatment
execution.
• Internal Target Volumes (ITV). It is a volume, generally asymmetric around
the CTV, that takes into account its variations in position, shape and size,
due for instance to movements connected to respiration or heart beat.
In some cases it is useful to delineate the Planning organ at Risk Volumes (PRVs),
which are volumes surrounding Organs At Risk (OARs), i.e. tissues or organs that
need absolutely to be spared in favor of the avoidance of crucial side effects; an
example of such organs is the spinal cord.
And to conclude, an important volume when talking of hypoxia is the Hypoxic
Target Volume (HTV).
3.2 The role of FMISO in Head and Neck Cancer imaging
Although nowadays 18F-FMISO is the most used radiotracer for the detection of
hypoxia, at the current state it has not reached the level of acknowledged drug
applicable in the oncological clinical practice, as conversely 18F-fluorodeoxyglucose
(18F-FDG) did for the enhancement of tumor metabolism in PET imaging.
Therefore it is useful to resume where the research has lead and what has confirmed
so far, in order to better understand what are the directions to pursuit for a further
validation and for the introduction of 18F-FMISO in the clinical use, at least for
what concerns head and neck cancers.
So far the studies carried out on the radiotracer related to HNC seem to agree on
the following aspects:
• The fractionation of the total dose in multiple consecutive delivery steps
leads to the re-oxygenation of the tumor, especially at the beginning of the
treatment (usually first 20 Gy / 10 fractions) [48,60,61].
• Different parameters, such as the maximum Standardized Uptake Value (SU-
Vmax), TBRmax, the TMR, hypoxic volumes, especially at the first-second
week of treatment, are factors that could predict the prognosis of the dis-
ease in radiotherapy and radiochemotherapy. They have proven to discrim-
inate reliably between responders, for which the standard RT is suitable to
eradicate the cancer, and non-responders, i.e. patients showing high corre-
lation to further recurrences due to high level of hypoxia [39, 47, 50, 61–64].
The same consideration applies for FMISO PET images of HNC patients ac-
quired before chemotherapy alone [40]. This point will be discussed in detail
in Subsection 3.3.
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These results are confirmed by statistical significance, however they can provide
methods only for the assessment of the biological responsiveness of a patient in
terms of speed of re-oxygenation of the tumor and possible outcome of the ther-
apy. They do not give straight answers to questions like "Is 18F-FMISO a reliable
radiotracer? / Are the obtained images reproducible?", "How do the hypoxic vol-
umes evolve in shape and localization during time?" and "Is it effectively possible
to counteract hypoxia in HNC with the use of RT? And if yes, how?". The answers
to these topics have been examined by different groups of research, but did not
conclude with definitive verdicts, due especially to the small size of the patients
cohorts involved in these clinical trials.
While the third question will be discussed in detail in Subsection 3.4, here the
attention is put on the first two.
The reproducibility of 18F-FMISO has been tested on different cohorts of HNC pa-
tients. A study of 2013 involving 11 HNC patients tested the repeatability of the
results comparing the values of SUVmax, TBR, TMR and hypoxic volumes between
two PET scans acquired with the same protocol 48 hours apart, achieving high cor-
relations (>90%) between the pairs of parameters [43]. A previous work revealed a
high correlation (71%) in uptake in a GTV voxel-by-voxel analysis between pairs of
PET pre-treatment images acquired 3 days apart for 20 HNC patients; however this
decreased to 46% when only the presumed hypoxic volumes were considered [65],
indicating the possibility of the presence of a bias term (chronic stable hypoxia)
and a fluctuating component (acute or cyclic hypoxia). But two problems here
arise: the hypoxic volumes were delineated with a threshold on the TBR, yet so far
any study showed the stability of radioactivity in the blood; moreover, the acquisi-
tions were made in temporal ranges of minutes too wide (117-195 min, and 126-195
min respectively for FMISO 1 and FMISO 2) for a reliable analysis (see section
2.2) [66]. There is also in literature the proposal of a model for tissue oxygenation
and FMISO dynamics that includes the contributions of chronic and acute hypoxia
separately [67]: here the high prevalence of chronic hypoxia to the cyclic one in
the cause of retention of FMISO in hypoxic volumes is proven (87% vs 13%); it is
also observed that, even varying the timepoint of the tracer injection along all the
acutely hypoxic cycle, the variability in FMISO uptake is not significative.
For what concerns the dynamic and morphology of hypoxia, a few studies showed
that the hypoxic subvolumes have different patterns of shape change during the
treatment (completely resolved, decreasing stable, decreasing unstable, increasing
hypoxia); the overall tendency in the majority of patients is a decrease in vol-
ume with a rather stable localization [68,69]; another study reports a geographical
miss of 20% between repeated 18F-FMISO PET images during the treatment in
HNC [70], most probably due to unpredictable changes in tumor vasculature at a
cellular level.
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3.3 Investigating the tumor response to radiotherapy in Head
and Neck Cancer patients with hypoxia tracers
The predictive value of PET imaging in Head and Neck Cancer is still matter of
study for all the hypoxia radiopharmaceuticals; however, so far 18F-FMISO con-
firmed in many more studies than for other tracers its capability of categorizing
the patients between RT responders and non-responders.
Among the other radiopharmaceuticals for detection of hypoxia, only 18F-FAZA
has been tested by more groups for predictive purposes.
One of the most relevant work is the one carried out by Mortensen et al., who ex-
amined data coming from 40 HNC patients undergoing RT or radiochemotherapy;
the hypoxic volumes where defined by a threshold of 1.4 on the TMR and 9 out 10
recurrences happened in patients defined as hypoxic, while the remaining patient
was considered non-hypoxic with a borderline TMR of 1.3 and did not complete
the therapy [71].
Similarly, Saga et al. proved, by a FAZA imaging analysis for 23 HNSCC patients
undergoing radiochemotherapy, that the TMR pre-therapy is the only prognostic
factor for determination of progression-free survival (p-value=0.01) [72].
For pre-RT 18F-FMISO imaging, one of the first and most important results, be-
cause of the number of patients involved (N=73), reveals as the strongest factor
associated to patient survival the TBRmax, followed by the HTV, in an univariate
analysis of pre-treatment PET images [62].
In another early study involving 15 HNC patients, the univariate analysis detected
a weak statistical significance (p-value close to 0.05) for the SUVmax and no sig-
nificance for the hypoxic fraction; here the negative prognosis was linked to tumor
recurrence, instead of the patient decease [73].
An analysis carried out by Kikuchi et al. on 30 HNSCC patients found high corre-
lations with treatment outcome (presence or absence of relapses) in SUVmax and
TMR parameters (p-values 0.02 and 0.04 respectively) [39].
Eschmann et al., by analyzing the clinical course of 13 HNC patients, found pre-
dictive power (presence of relapses) in SUV with images acquired 4 hours post
injection (p-value=0.04), but not for the same factor 2 hours post injection (p-
value=0.16); also a threshold of 1.6 on TMR 4 hours p.i. allowed to perfectly
discriminate between responders and non-responders [47].
To conclude this sequence of pre-radiotherapy image analyses it is noteworthy the
phase II clinical trial developed by Welz et al., which revealed that the branch
of 10 HNSCC patients receiving counter-hypoxic dose escalation presented better
outcomes in terms of local tumor control with respect to the branch of 10 patients
receiving the standard radiotherapy (70.0% vs 44.4%). In this case a baseline dy-
namic FMISO PET-CT was used to generate a value of malignancy for each voxel
depending on hypoxia and tumor perfusion; the HTV was determined by a thresh-
old on the coefficient of malignancy [63].
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Repeated 18F-FMISO imaging for HNC prognosis was carried out by three groups.
Zips et al. enrolled 25 HNC patients, imaged once before and three times dur-
ing radiochemotherapy; they demonstrate that in an univariate analysis, the most
powerful predictive parameters for local recurrences are the TMR and the SUVmax
at the second week of treatment (p-values of 0.008 and 0.015, hazard ratios of 4.25
and 3.85, respectively) [50].
Wiedenmann et al. obtained similar results; in fact, they analyzed 16 HNC pa-
tients in three time points before and during radiochemotherapy, finding the best
correlation between presence of tumor recurrences and TMR during the second
week of treatment (p-value=0.016) [61].
Similar results, coming from a pooled cohort of 50 HNC patients undergoing ra-
diochemotherapy, are given by the work of Löck et al. They indicate that the
prognosis can be reliably determined by the hypoxic volume before the treatment,
at week 1 and 2 (p-values of 0.008, 0.01 and 0.008) and by the TMR at week 2
(p-value=0.017) [64].
Recently, a novel approach conducted by Lazzeroni et al. proposed a new method
for revealing in a systematic way the predictive power of FMISO. The process con-
sists in the temporal evaluation of the distribution of pO2 values in the hypoxic
volumes; indeed, often multiple FMISO imaging sessions are taken before and dur-
ing the therapy and today it is also possible to convert the uptake into oxygen
tension maps [4]. The objective is to determine how the tumor re-oxygenates dur-
ing the course of RT, by looking at how the histograms representing the oxygen
tension distributions evolve in time (normally three time points are considered:
one before and two during the therapy). Looking in detail the algorithm, initially
the histograms of the hypoxic volumes are fitted with a log-normal distribution,
obtaining three functions (f1, f2 and f3) characterized by the relative parameters;
they can be seen as the known inputs and outputs of two blocks representing the
re-oxygenation processes (unknown), described by the functions (or impulse re-
sponses, using a term of the systems theory) g1 and g2. Therefore, g1 convolves
with the oxygen tension distribution at the first time point (f1) to give the second
(f2), while g2 convolves with the second distribution (f2) to give the third (f3). The
process of convolution can easily be substituted by the application of the Fourier
transform and anti-transform, replacing the convolutions with the products [5].
More details on the methods are given in Subsection 4.4.2.
The application of this method on a big cohort of patients could lead to the classifi-
cation of different patterns of tumor re-oxygenation, with the possibility of predict-
ing the prognosis of the disease after the treatment by looking at the parameters
of the re-oxygenation function.
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3.4 Possible dose escalation strategies exploiting FMISO imag-
ing
To date the treatment plans in RT do not use the information provided by func-
tional imaging of hypoxia; nevertheless, several groups tested the feasibility of
incorporation of radiosensitivity parameters connected to hypoxia in the so-called
"dose painting", i.e. the delivery of higher doses to the hypoxic volumes to coun-
teract tumor cells with low pO2 [74].
The dose painting techniques developed so far can be subdivided into two groups
[74]:
• Dose Painting by Contours (DPBC). This method is usually based on the use
of a fixed lower threshold, e.g. on the TBR or TMR, to define the hypoxic
subvolumes; generally this permits an easier software implementation and the
production of an uniform dose boost prescribed to the hypoxic subvolume.
Chang et al., for instance, evaluated the use of a protocol for HNC, where
the hypoxic target is delineated by a TMR ≥ 1.5 and the correspondent PTV
receives a dose of 84 Gy, when in the standard treatment the maximum dose
delivered to the PTV is of 70 Gy [75]. Choi et al. instead explored the delivery
from 2.6 to 3.6 Gy more per fraction with respect to standard treatment to
hypoxic targets defined by a tumor-to-cerebellum ratio of 1.3 [76].
• Dose Painting by Numbers (DPBN). While DPBC works generally on prop-
erties of the full patient volume, such as the histogram of uptake values,
this approach is voxel-based. The dose to deliver to each voxel is calculated
and planned by the use of biological parameters, such as the pO2 level or
the growth rate of cells in some cases; these maps can be obtained by simple
models, relating the uptake to the correspondent parameter in a linear way, or
by more complex and better describing representations, such as exponential
or sigmoidal models [4, 38].
The research by now has spent more energy on DPBC; different single-center works
tested by simulation the feasibility of dose painting for IMRT and VMAT, obtaining
in general a considerable increase in TCP and stability or a small increase in NTCP
when a pre-treatment 18F-FMISO image is acquired [75–78]; this is proved also by
the fact that loco-regional recurrences in HNC arise mainly from hypoxic subvol-
umes in the primary GTV [79]. Similar results have been obtained for a phantom
simulation with 60Cu-ATSM [80] and repeated 18F-FAZA PET images [81]. But,
although the high correlation between FMISO uptake and tumor control, the pat-
terns of re-oxygenation are pretty variable during the therapy, with the necessity of
utmost care during the planning and the use of multiple imaging during the treat-
ment [75, 77, 78, 81, 82]. Thus an adaptation of the treatment along the different
sessions is generally needed for hypoxic patients [70]. By now there are also doubts
concerning the threshold to use on TMR (see Table 1): a study of Henriques de
Figueiredo et Al. based on pretreatment FMISO PET images demonstrated that
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the static threshold method gives double hypoxic volumes when compared to an
adaptive threshold or to a stochastic method, indicating that probably a fixed
threshold is too conservative, as it could include parts of the tumors with levels of
pO2 higher than 10 mmHg, that could be misleading [36].
The DPBN branch has been concentrating on the power and significativity of bio-
logical features: indeed the relationships between tracer retention and pO2 values
are not linear and the model supporting the oxygen transport to tumor capillary
beds is complex; if we add to this the fact that what we can image with PET
are voxels having a resolution on the order of the mm, while the oxygen transport
to tissues happens on the µm scale, then a model connecting the two domains is
required [74].
Different paths based on different PET imaging modalities have been examined.
The first is founded on specific doubts about the use of static PET images, because
they lack of an important parameter characteristic of each tumor microenviron-
ment: the perfusion efficiency; the combination of the perfusion in the tumor mi-
croenvironment with the tracer uptake would reveal specific patient information,
with a consequent categorization of the patient tumor re-oxygenation and thus the
possibility of a specific tailored therapy [73]. This can be obtained from dynamic
PET images, for which different models have been developed [83, 84]; simulations
gave also better results when compared to uniform dose boosts in terms of TCP [85];
nevertheless, this analysis is not yet feasible in the clinical practice because of more
complex imaging protocols.
An alternative solution exploiting the relative higher simplicity of static uptake
maps is the use of an oxygen transport model that can connect directly the tracer
uptake domain to the oxygen partial pressure domain; a possible non-linear con-
version function had already been presented in Subsection 2.2. In the same paper
of Toma-Dasu et al. describing the sigmoidal uptake model, three treatment ap-
proaches for hypoxia have been advanced and compared to the standard radiation
treatment. The first method adopts the tumor radiosensitivity at a pre-clinical
level, considering hypoxia as a stable phenomenon throughout the time; a dose-
modifying factor associated to the Linear Quadratic model is therefore used to
deliver a dose boost to the hypoxic subvolumes. The second approach takes into
account variations in tumor oxygenation over time, by including in the planning
FMISO images acquired even during the treatment. The last involves a segmen-
tation of the tumor volume in CTV, GTV and HTV, and an escalation of the
standard dose to each segment inversely proportional to the steepness of the corre-
spondent dose-response curve; this results in an effective dose to the whole tumor
volume, as the model simulation confirmed, giving the best results in terms of
tumor coverage and tumor control. Despite its clinical utility, the third method
requires more technical resources and would be therefore suitable for patients pre-
senting extensive tumor hypoxia; indeed the second method demonstrated only a
fewer tumor coverage achieving the same TCP, and thus, being also less resources
demanding, would be more appropriate when patients present not extensive or even
absent hypoxia [38].
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It remains anyway fundamental to investigate precisely how the hypoxia patches
evolve during the course of the treatment and what are the contribution of cyclic
and chronic hypoxia in FMISO PET imaging.
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4 Materials and methods
4.1 Patients
In this study, between 2014 and 2017 thirty HNSSC patients enrolled for a clin-
ical trial and have been treated with radiotherapy in the Universitätsklinikum of
Freiburg with a total dose of 70 Gy fractionated in five fractions of 2 Gy per week;
for each patient two or three clinical target volumes, shown in Fig. 4.1 for one
representative patient, were defined:
• HN1, the volume receiving 50 Gy of dose, and
• HN2, boost volume within HN1, receiving further 10 Gy of dose + HN3,
boost volume within HN2, receiving further 10 Gy of dose, or
• HN2, boost volume within HN1, receiving 20 Gy of further dose.
Figure 4.1: Clinical Target Volumes indicated by the medical team for dose
delivery in the tumor volume. HN1 is marked with blue, HN2 with red, while
HN3 with green color.
Also, concurrently with RT, chemotherapy with three cycles of cisplatin 100 mg/kg/d
(or carboplatin in case of chronic renal insufficiency) were administered. At the date
of diagnosis the median age was 60 years, with a range of 34-77 years; the median
follow-up time was 21.54 months, with a range of 1.51-49.28 months. 6 patients
deceased during the experiment due to local recurrences or other circumstances,
while in total 14 patients presented recurrences during the follow-up period.
The patients’ imaging procedure consisted of an initial planning CT before the
treatment (12.07 ± 3.52 days, range 5-22 days), of one co-registered 18F-FDG PET-
CT before the treatment (8.59 ± 5.95 days, range 0-31 days) for a better tumor
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delineation and to three co-registered 18F-FMISO PET-CT at different imaging
stages: the first before the treatment (5.65 ± 2.66 days, range (-2)-8 days); the
second after a mean dose of 16.03 ± 4.56 Gy (11.10 ± 3.92 days after the beginning
of the treatment; range 6-23 days); the third after an overall mean dose of 46.30 ±
5.67 Gy (33.03 ± 5.34 days after the beginning of the treatment; range 27-51 days).
Fig. 4.2 introduces an example of the available set of images for one representative
patient.
In Table 2 the main characteristics of the patients and the timing of the FMISO
imaging are reported.
Figure 4.2: Sample of available images (Patient 22): planning CT on the left;
CT-FDG PET pair on the high left corner; CT-FMISO PET 1 on the high right
corner; CT-FMISO PET 2 on the low left corner; CT-FMISO PET 3 on the low
right corner.
4.2 Protocol of PET-CT image acquisition
The patients were not required to fast before the imaging sessions. The CT/PET
scanner adopted comes from Philips brand, the specific model being GEMINI TF
Big Bore. The position of the patients was the same used for the radiotherapy
treatment, while the static imaging process started 167 ± 15 minutes after the
injection of 302 ± 17 MBq of 18F-FMISO and lasted 20 minutes.
4.3 Image registration in RayStation
The analysis conducted on the three pairs of PET-CT images acquired for each
patient before and during the treatment has been possible thanks to an hybrid De-
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Table 2: Patients’ characteristics
No. Age
Follow-
up time
(months)
Time to
loco-
regional
recurrence
(months)
Time to
decease
(months)
Delivered
dose at 2nd
FMISO
PET (Gy)
Delivered
dose at 3rd
FMISO
PET (Gy)
1 60 36.92 N.A. N.A.
2 52 24.33 16.79 24.33 N.A. N.A.
3 53 12.13 5.18 12.13 20 56
4 51 25.77 14 44
5 61 28.85 6.95 12 42
6 54 23.41 10.36 22 40
7 66 15.15 5.18 26 50
8 51 19.48 14.56 12 40
9 60 11.18 20 44
10 70 11.54 12 42
11 56 8.56 14 44
12 60 3.61 12 40
13 60 48.23 12 52
14 49 43.34 20 46
15 60 44.30 8.16 20 48
16 63 43.08 12.82 16 54
17 63 36.75 N.A. 36.75 40
18 41 34.23 6.66 34.23 18 46
19 54 8.95 8.95 20 50
20 77 36.95 20 59
21 69 16.03 10.52 14 41.13
22 34 1.51 24 54
23 67 15.74 15.74 12 40
24 42 24.79 7.05 20 52
25 60 5.97 8 38
26 67 21.54 12 50
27 57 19.34 9.70 12
28 57 10.72 7.80 12 54
29 67 8.62 14 46
30 65 3.02 14 46
formable Image Registration (DIR) implemented in a research version of RaySta-
tion [86]. This technique has been recently introduced for HNC; although its spatial
accuracy has proven to be high, further validation of the algorithm is required [87].
The algorithm at the base of hybrid DIR in RayStation is called ANACONDA,
standing for "ANAtomically CONstrained Deformation Algorithm", which com-
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bines intensity information with anatomical information given by contoured image
sets, with the purpose of avoiding as much as possible the smoothing of images con-
taining only intensity information and keep the whole anatomical information [86].
Algorithms involving only the first approach try to match the image intensities
voxel-wise or patch-wise, loosing the guarantees on the reliability of the anatom-
ical matching, especially in low-contrast regions; the second group instead uses
hundreds of landmarks pointed by the specialist on meaningful and evident struc-
tures, which are then registered to the target image and used to derive a defor-
mation vector field: the drawback in this case is a reduction in accuracy where
landmarks are less dense. The objective (non-linear) function maximized adopted
by ANACONDA is the weighted sum of [86,87]:
• an image similarity term (e.g. a correlation coefficient), based on a combi-
nation of image intensities and geometrical structures; in this way only the
benefits coming from the two approaches are achieved, while the drawbacks
are avoided.
• a grid regularization term, to keep the image grid smooth and invertible;
• a penalty term, when controlling structures (such as the patient contour) are
present.
Each patient was registered following two separated steps: first, a rigid registra-
tion based on the bony anatomy; second, a deformable registration based on the
previous algorithm.
The process of registration (rigid transformation + hybrid DIR) for each patient
and each pair of PET-CT volumes consisted in the registration of the low dose
CT (the one acquired concomitantly with the correspondent PET) to the planning
high dose CT, while the application of the latter transformation to the PET scan
was implicit, as they belong to the same frame of reference.
This method lets every pair of CT-PET volumes to be co-registered and finally
registered to the reference planning CT. Fig. 4.3 gives a schematic representation
of the registration process and Fig. 4.4 shows an example of coregistered images.
4.4 Methodology
4.4.1 Analysis of the influence of the reference region
Once the registration procedure is completed, a set of superimposable anatomical
and functional images for each patient is available for further analyses.
The following step is the application of the model described in Subsection 2.2 in
order to obtain maps of oxygen partial pressure, by using equation 4. Particular
attention should be put on the choice of the Well-Oxygenated Volumes, together
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Figure 4.3: Representation of the registration process: at the beginning, the
CT-PET coupled images are inherently registered; what follows is the hybrid
deformable registration of the low-dose CT to the planning CT; the same
transformation takes automatically place in the PET images, because they belong
to the same frame of reference of the corresponding CT images. As a result, all
the CT-PET pairs are registered with the planning CT and between themselves.
with their reference values.
Several WOVs have been tested, but some of them were discarded before further
considerations. Indeed two first attempts were the cerebellum and the ear lobe; the
problems found with them were the absence of cerebellum in many of the CT-PET
acquisitions and the inconstancy of the position of the ear lobe after the hybrid
deformable registration, due to the small size of the ROI located at the border of
the patient’s anatomy. Hence two kinds of reference region were considered: the
posterior deep neck muscle and the shoulder muscle; it was not possible to extend
the choice of the reference to other regions, since the PET volumes included a nar-
row band of the body focused on the tumor volume; in fact, as Fig. 4.4 displays,
in most of the patients the visible parts were the inferior part of the head, the neck
and part of the shoulders.
For all the patients but 9 the neck region was already delineated by a medical
doctor, while for the others a box with dimensions 5x4x2 cm3 was manually drawn
and considered as a surrogate of the neck delineation. For all the patients a sphere
of radius 1.25 cm (volume 1.95 cm3) was generated in the shoulder muscle in a
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Figure 4.4: Example of hybrid registration (Patient 22). From top to bottom, left
to right: planning CT overlapped with PET FDG, PET FMISO 1, PET FMISO
2, PET FMISO 3; CT-PET FDG; CT-PET FMISO 1; CT-PET FMISO 2;
CT-PET FMISO 3, respectively.
region of low CT density. Fig. 4.5 reports an example of such regions.
The three FMISO PET images were then converted into oxygen tension maps
through the non-linear model presented in section 2.2. The research version of
RayStation implements a module called Functional Analysis that permits to apply
the sigmoidal model to the data and export them if necessary for further analyses
with other softwares. With the parameters values for A, B and C defined previously
three maps have been generated for each FMISO PET image, corresponding to the
three following WOVs:
• neck muscle, with reference value 29 mmHg;
• neck muscle, with reference value 60 mmHg;
• shoulder muscle, with reference value 60 mmHg.
The last two reference values come from values adopted in the original model [38],
while the first has been chosen because a work of Carreau et al averaged different
studies, finding 29.2±1.8 mmHg as pO2 value for skeletal muscles [18].
For each map the HTV inside HN2 (one of the CTVs) was defined through the
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(a)
(b)
(c)
Figure 4.5: Examples of adopted WOVs (FMISO PET 1 coregistered images are
superimposed to the planning CTs): 4.5a. Patient 23, neck box; 4.5b. Patient 11,
manually drawn neck region; 4.5c. Patient 11, sphere in the shoulder region.
standard threshold of 10 mmHg. In order to compare this work with the others in
the topic (see Subsection 2.2), the hypoxic volumes have been defined also in the
FMISO PET images, choosing 1.4 as lower threshold for the TMR and the neck
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muscle as reference; indeed, as Table 1 displays, this is the most common practice.
The quantification of the similarity between the pairs of volumes derived from the
conversion functions and the standard method using TMR ≥ 1.4 has been done by
using the DICE coefficient. The DICE coefficient for two volumes, DICE(V1, V2),
is defined as the ratio between their intersection, V1 ∩V2, over their union, V1 ∪V2.
Another element evaluated is the correlation between the curves representing the
trend of hypoxic volumes during the therapy. This was accomplished by calculating
the normalized cross-correlation coefficient with zero lag between signals, i.e. for
the two signals x and y the normalized cross-correlation coefficient is Rxy(0) =∑3
n=1
xn·yn√∑3
n=1
xn·xn·
∑3
n=1
yn·yn
; here, 0 is the maximum shift between the signals, while
3 is the number of time points corresponding to FMISO PET images.
4.4.2 Modeling parameters of re-oxygenation
The aim of this part of the study was to establish first of all the best distribution
fitting the histograms of pO2 values in the HTVs, and, after this, to find a pattern
of re-oxygenation functions connecting the fitted distributions among the three
different time points.
The theory behind this is quite simple. Considering the three oxygen tension
maps, it is possible to represent the values of pO2 by histograms. Let us suppose
that their shape is fitted by three functions, f1, f2 and f3; then we can imagine
this like a system (see Fig. 4.6), where the impulse response, reox, characterizes
the re-oxygenation process. By the systems theory, the output is given by the
convolution of the impulse response with the input; moreover, from the Convolution
Theorem the operation becomes the product of the Fourier transforms of the input
and of impulse response. In formulas, considering for instance the first block,
F2 = REOX ·F1, where F2 = F{f2}, REOX = F{reox} and F1 = F{f1}. A final
Fourier anti-Transform of the found REOX furnishes the desired re-oxygenation
function reox: reox = F−1{REOX}.
Since the choice of the posterior neck muscle corresponds to the same region
adopted in the standard method, while the reference value of 29 mmHg is granted
by the literature, this analysis has been conducted only for the maps coming from
this latter case.
Therefore the following procedure has been followed for each patient:
1. From the pO2 map derived from the first FMISO PET, the HTV inside the
HN2 has been selected.
2. The selected region has been expanded 1 cm in each direction, in order to
consider the HTV with the surrounding tumor environment.
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Figure 4.6: Schematic representation of the re-oxygenation system among the
three time points in the therapy.
3. The expanded region has been intersected with the HN2, as by definition it
is not expected to have tumor cells outside the CTV.
4. The region obtained has been copied in the second and third maps derived
respectively from the second and the third FMISO PET image of the patient.
5. The three maps of pO2 values have been exported to generate the histograms
to fit through Matlab v. 2017b and Origin v. 2018b.
6. Different distributions have been evaluated for the fitting of the histograms
and the ones with the best fitting were kept for further comparisons; in this
way the functions f1, f2 and f3 were generated. Also the influence of the
binning of the data with different widths and different methods was evaluated.
7. The functions f1, f2 and f3 were shifted into the frequency domain applying
the Fourier Transform, obtaining F1, F2 and F3.
8. The re-oxygenation functions REOX1 (mapping F1 to F2), REOX2 (map-
ping F2 to F3) and REOX3 (mapping F1 to F3) were calculated.
9. The inverse Fourier Transform provided the desired re-oxygenation functions
in the initial domain, reox1, reox2 and reox3.
In particular for the point 6 the concentration has been posed on the LogNormal
distribution and on the Burr distribution; the former is given by the following
density:
f(x) = 1
x
√
2pi
· exp[− (ln(x)− µ)
2
2σ2 ], (5)
where µ and σ are respectively the mean and the standard deviation of the distri-
bution; the Burr density instead is given by:
f(x; c, k, λ) = ck
λ
· x
c−1
λ
· [1 + x
λ
c
]−k−1, (6)
where c, k and λ are three parameters.
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5 Results
In this Section, the results obtained will be presented structured in two parts. The
first part shows how the choice of the WOV can affect the contouring of the hypoxic
subvolumes. The second one deals with the mathematical characterization of the
re-oxygenation curves.
5.1 On the selection of the well oxygenated reference region
The pO2 maps generated by using the different WOVs returned results character-
ized in general by rather considerable differences in terms of extension of hypoxic
volumes and localization. In the following an example of images obtained for a
representative slice of Patient 9 is displayed; it is also possible to see the evolution
of hypoxia estimated by the three methods based on the conversion model and by
the standard method based on DPBC (Fig. 5.1-5.3 and Fig. 5.4, respectively). The
oxygen tension maps given by Fig. 5.1 show the change in location and size during
treatment of the hypoxic region in the tumor when using as WOV the deep neck
muscle with a reference value of 29 mmHg; in this case, the initial volume almost
disappeared already after the second week of treatment. In Fig. 5.2, instead, the
map of pO2 values never displays values below the threshold of 10 mmHg; this was
found in all the patients but 2 when using the WOV corresponding to the posterior
deep neck muscle with a reference value of 60 mmHg. The case of Fig. 5.3, where
the WOV adopted is the sphere in the shoulder region with 60 mmHg as reference,
is different from the previous two: here, indeed, the volume found is large already
before the treatment and keeps staying high, with a slight decrease, until the fifth
week of treatment. Finally, Fig. 5.4 shows the standard method based on the
threshold of 1.4 on the Tumor-to-Muscle Ratio, giving hypoxic volumes definitely
larger in all the FMISO PETs than the three conversion maps.
It is of interest to compare the minimum value of pO2 inside the hypoxic targets,
the hypoxic volumes and the similarity between pairs of volumes. The first two are
displayed in Fig. 5.5 for each FMISO PET and each patient, while the similarity
is further on discussed in this Subsection.
As reasonably expected, the general trend for the minimum level of pO2 is a slight
increase during the treatment, as tumor re-oxygenation takes place; at the same
time the hypoxic volume decreases in most of the patients.
As already described, the use of the posterior neck muscle as WOV with 60 mmHg
of oxygenation reference leads to an unlikely result, i.e. only Patients 1 and 20
resulted hypoxic before the treatment and after that any trace of hypoxia is found.
Conversely, the HTV given by the conventional method for this dataset is always
non-zero for all the patients, with rather high values for every PET imaging; this
is also an improbable case, as generally for HNC studies the percentage of hypoxic
patients decreases considerably during the treatment, while this dataset does not
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Figure 5.1: Example of pO2 maps generated by using as WOV the posterior deep
neck muscle with 29 mmHg as assigned oxygenation level. Every row is related to
the correspondent FMISO PET (1, 2 and 3); HN2 (magenta) and HTVs (green)
are delineated.
Figure 5.2: Example of pO2 maps generated by using as WOV the posterior deep
neck muscle with 60 mmHg as assigned oxygenation level. Every row is related to
the correspondent FMISO PET (1, 2 and 3); HN2 (magenta) and HTVs (green)
are delineated.
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Figure 5.3: Example of pO2 maps generated by using as WOV a sphere in the
shoulder region with 60 mmHg assigned oxygenation level. Every row is related
to the correspondent FMISO PET (1, 2 and 3); HN2 (magenta) and HTVs
(green) are delineated. Sagittal frame in FMISO 1 and coronal frame in FMISO 2
present an artifact connected to software visualization.
Figure 5.4: Hypoxic volumes determined on the FMISO PET images with the
standard method (TMR ≥ 1.4). Every row is related to the correspondent
FMISO PET (1, 2 and 3); HN2 (magenta) and HTVs (light blue) are delineated.
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(a)
(b)
(c)
Figure 5.5: Plots of the minimum pO2 values in the hypoxic targets resulting
from the uptake model application and of the hypoxic volumes found with the
four different methods for FMISO PET 1 (5.5a), 2 (5.5b) and 3 (5.5c).
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Figure 5.6: Evolution of HTV values during the treatment by using the uptake
conversion model and as WOVs the deep neck muscle with 29 mmHg oxygenation
reference and the shoulder region with 60 mmHg oxygenation reference.
show any disappearance of hypoxia along the treatment.
The use of the neck muscle with 29 mmHg reference and of the shoulder region with
60 mmHg reference as WOVs leads to about 70% agreement on the classification of
the 30 patients as hypoxic or non-hypoxic. However, it should be mentioned that
the volumes have different extensions and spatial localization; indeed, the DICE
coefficient for the hypoxic volumes found with these two methods for FMISO PET
1 has a mean value of 0.16 ± 0.21, with a median of 0.05, indicating a poor spatial
matching. Despite this, their evolution during the weeks of treatment are similar,
with corresponding growths and decreases in most of the cases, as Fig. 5.6 depicts
for some of the patients in the available dataset: even if with different magnitudes,
the two methods have analog behaviors for instance in Patients 2, 9 and 23 (in total
in 25 patients out of 30); in some case (5 patients out of 30), like for Patient 8, they
present different trends. Overall the mean normalized cross-correlation coefficient
for the 30 pairs of curves is 0.82 ± 0.25.
For what concerns the standard method, since the choice of a TMR ≥ 1.4 does not
seem to be suitable for this patient dataset, additional analysis was performed to
study in detail this aspect. Interestingly, the HTV corresponding to TMR ≥ 1.4
is not significantly similar to the volume contoured in the pO2 map defined with
the WOV located in the deep neck muscle with 29 mmHg as reference (DICE =
0.05 ± 0.06, median 0.02); still, they are significantly similar when the threshold
for hypoxia is raised to 18 mmHg as median value for all the patients in the study
(mean value equal to 18.0 ± 0.5 mmHg), instead of the standard hypoxia threshold
of 10 mmHg (DICE = 0.79 ± 0.17, median 0.82). Fig. 5.7 makes this concept clear
for one representative patient.
5.2 On the calculation of re-oxygenation functions
Firstly, an analysis of the influence of the binning of the data and of the method
adopted for the fitting was done.
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(a) (b) (c)
Figure 5.7: Similarity of volumes when changing the threshold for hypoxia
(Patient 21); HN2 in magenta and HTV in green or light blue. Subfig. 5.7a shows
the pO2 map obtained by using the deep neck muscle as WOV and 29 mmHg as
reference, while the standard threshold for hypoxia (10 mmHg) is maintained;
Subfig. 5.7b represents the same map with a threshold for hypoxia raised to 18
mmHg; Subfig. 5.7c represent the FMISO PET 1 uptakes with the HTV defined
by a TMR ≥ 1.4.
In particular, the binning of the pO2 data (i.e. the choice of the bins width on the
X axis of Fig. 5.8) contained in the expanded HTV has an influence when using the
Least Squares method. The Least Squares method tries to find the best parameters
of the given distribution, fitting the middle points of each bin by minimizing the
sum of the squared residuals; therefore, a modification of the bins width leads to
a shift of the bin centers and to different counts. The consequence is a variation
in the parameters of the fitting distribution, as shown in Fig. 5.8. It may seem
reasonable to apply this method when trying to fit a given distribution, because it
gives the possibility to decide the level of "noise" of the data by choosing wider or
narrower bins. But it is necessary to point out that the Least Squares method is
exploitable when some basic requirements are fulfilled; in particular, for this fitting
problem, the most relevant hypotheses to respect are the following three:
• measurement errors must be symmetric;
• along the distribution the variability must be the same;
• the measurements must be independent,
where with measurement it is intended the count for a specific bin. Here the three
hypotheses are violated, because: first, the bin counts are non-negative and thus
measurement errors are asymmetric, especially when the count is close to 0; sec-
ond, the tails have different variability with respect to the center of the distribution;
third, the bin counts, having a fixed sum, are not independent values.
For these reasons an alternative method, based on Maximum Likelihood, has been
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(a)
(b)
Figure 5.8: Impact of the choice of the bin width on the fitting parameters when
using Least Squares (fitting with LogNormal distribution): 5.8a. Bin width=1
mmHg; 5.8b. Bin width=2.5 mmHg.
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Figure 5.9: Normalized pO2 histograms of the three maps and correspondent
fitting curves (LogNormal and Burr) obtained with the Maximum Likelihood
Estimation for the Patient 08.
considered. It does not present the issue of the binning of the data, as it estimates
the parameters of the fitting distribution by adopting the raw data, instead of
grouped data. Even though the results obtained are reliable, a possible drawback
of this method is that the found curve might be noisier, as in the raw data can be
present abrupt variations in the pO2 distribution.
An example of the comparison between the fitting of the two distribution is rep-
resented in Fig. 5.9, where it can be visually inferred that the Burr distribution
seems to fit the data better than the LogNormal. The mentioned increased "good-
ness" of fit is also reflected by a mean adjusted R-square value of 0.97 for the Burr
distribution, versus a value of 0.85 for the Log-Normal.
It was shown that different functions used for fitting the histograms for pO2 render
different re-oxygenation functions characterized by different graphical representa-
tions, displayed for one patient in Fig. 5.10.
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Figure 5.10: Representative re-oxygenation functions (reox1, reox2 and reox3)
obtained after the use of two fitting distributions (LogNormal and Burr) of the
pO2 histograms.
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6 Discussion
Hypoxia is one of the leading causes of failure of radiotherapy in head and neck
cancer due to an increase in the cells radioresistance of a factor up to about three
times [2]. The imaging of hypoxia in the last decade focused especially on the use
of positron emission tomography; meanwhile 18F-FMISO has affirmed as the stan-
dard radiotracer for the purpose [3]. Many efforts have been put on the research of
novel methods for the dose painting to the more radioresistant volumes in tumors,
even though none of them has been officially introduced in the clinical routine.
The dose painting by contours has been widely acknowledged so far, giving straight-
forward techniques for the contouring of the hypoxic subvolumes based on a global
threshold on the uptake values and for homogeneous escalated dose distribution.
On the other hand, despite an easier dose boost implementation, the dose results
uniform in the hypoxic target and not necessarily follows a biological map of the
tumor radioresistance [74].
For some years, instead, a parallel path based on dose painting by numbers has
revealed approaches relying on the radiobiological features of the tumor microenvi-
ronment. A recent FMISO uptake model allows to transfer values from the tracer
uptake domain to the oxygen partial pressure one [4]; the obtained maps acquire
biological meaning, with consequent better descriptions of the tumor microenvi-
ronment and the possibility of establishing functions of re-oxygenation, whenever
multiple acquisitions during the treatment are available.
The present work wanted first of all to explore the influence of the choice of the
Well-Oxygenated Volume and its reference value, in order to set the bases for the
introduction of a standard method for the delineation of the hypoxic subvolumes.
Secondly, the histograms related to the latters have been examined, aiming to find
their best fitting distribution and subsequently define a finite set of possible re-
oxygenation functions, carrying on a task explored in the past year for a restricted
dataset of two patients (three lesions in total) [5].
For the definition of the hypoxic targets, the well-oxygenated regions studied were
a sphere in the shoulder with a reference value of 60 mmHg and the posterior deep
neck muscle with reference values of 29 mmHg and 60 mmHg, while a standard
approach by thresholding at 1.4 the ratio between tumor and neck muscle uptakes
was accounted for comparison.
The neck muscle with reference of 60 mmHg does not seem to be a reliable WOV,
indeed only 2 patients out of 30 in the dataset result hypoxic, a fraction not met
by histologic analyses.
Instead, the first two WOVs accord in a relevant fraction of the cases when it comes
to establish whether a patient presents hypoxia or not; however the determination
of the shoulder region is not univocal and often is not visible in the PET acquisi-
tions for HNC.
Unfortunately these volumes do not agree with the standard method, since it classi-
fied all the patients as hypoxic with quite large volumes. Presumably the threshold
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of 1.4 often adopted in clinical practice was not suitable for this patients’ dataset.
But a remarkable finding came from the comparison between the uptake volumes
and one of the pO2 maps, the one resulting from the choice of the posterior deep
neck muscle with 29 mmHg as reference. Their associated hypoxic targets were
indeed nearly matching in space, given the assumption of setting the threshold for
hypoxia at 18 mmHg, instead of 10 mmHg. This may lead to draw two conclusions:
• that the normally used threshold of 1.4 for the TMR might be actually too
conservative, being linked to an higher threshold for hypoxia than the stan-
dard 10 mmHg;
• that the uptake model for FMISO and for HNC gives volumes consistent with
the conventional method, when the chosen WOV is the posterior deep neck
muscle with a pO2 reference value of 29 mmHg, even though a shift of the
threshold for hypoxia was here necessary.
It was shown that the mathematical expression of the different functions used for
the fitting of the oxygen distribution expressed as histograms has a high influence
on the graphical representation of the re-oxygenation function. This result is war-
ranting further investigations with respect to the interpretation of the shapes of
the different re-oxygenation functions both in terms of signal processing, but also
in terms of the physiological underlining processes. The results should, however, be
put into the boarder context of the overall aim of the study, namely finding one (or
several) mathematical description for the re-oxygenation functions, reproducible
and robust to variations in the original shape of the histograms, characterized by
sets of parameters that correlate with the clinical observations and hence that could
be used for making predictions regarding the treatment outcome. The accuracy of
these function with respect to the original fitting is not a critical issue as long as
the pattern of response could be predicted based on their shapes or parameters.
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7 Conclusions
Hypoxic tumors make the delivery of radiation therapies less effective; the dose
painting to the hypoxic subvolumes is required to increase the tumor control. The
FMISO uptake model proposed by Toma-Dasu is useful to describe the radiore-
sistance of the cancer tissues as a map of pO2 values, with which it is possible to
boost the dose to the cells more reluctant to eradication. However, in this context
a reference oxygenated tissue needs to be chosen and the present thesis showed how
the choice of the WOV and its reference value are crucial for the representation of
the final oxygen partial pressure map. A good candidate reference for HNC has
been found in the posterior deep neck muscle, when assigning to it a pO2 equal to
29 mmHg. The goodness of this choice has been determined by a comparison with
a method currently considered a standard for the contouring of hypoxia in HNC
and derived from the literature, that is the use of a threshold equal to 1.4 on the
tumor-to-muscle ratio, where the muscle considered is generally the neck muscle.
Nevertheless, further efforts should be put on understanding to which threshold
for hypoxia the standard method is corresponding, as from the analyses here con-
ducted it seems to correspond to a threshold of 18 mmHg, almost double with
respect to the one general assumed, 10 mmHg.
Conscious of the fact that these considerations lay on a quite rich dataset for a
single study and could have a certain impact on the current scene, they clearly
deserve to be confirmed by other centers of research, repeating similar results in
analogous conditions, before final conclusions on the subject could be drawn and
possible clinical trials with dose painting delivered with the aid of the presented
method could start.
The re-oxygenation functions found with the method proposed by Lazzeroni et al.
have shapes depending on the distribution used to fit the histograms containing
the pO2 values in the neighborhood of the hypoxic volumes. Further research is
needed for understanding the correlation between the shapes or parameters of such
functions and the outcome of the therapy.
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